Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry

Abstract Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide semi-quantitative results. Here, we describe a nove...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	John V. Dzimianski, Nicholas Lorig-Roach, Sara M. O’Rourke, David L. Alexander, Jacqueline M. Kimmey, Rebecca M. DuBois
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/732073a67aad4d4b950541e95d82a053
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:732073a67aad4d4b950541e95d82a053
record_format	dspace
spelling	oai:doaj.org-article:732073a67aad4d4b950541e95d82a0532021-12-02T12:33:04ZRapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry10.1038/s41598-020-78895-x2045-2322https://doaj.org/article/732073a67aad4d4b950541e95d82a0532020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78895-xhttps://doaj.org/toc/2045-2322Abstract Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide semi-quantitative results. Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies. Our biolayer interferometry immunosorbent assay (BLI-ISA) utilizes single-use biosensors in an automated “dip-and-read” format, providing real-time optical measurements of antigen loading, plasma antibody binding, and antibody isotype detection. Complete semi-quantitative results are obtained in less than 20 min. BLI-ISA meets or exceeds the performance of high complexity methods such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay. Importantly, our method can be immediately implemented on existing BLI platforms for urgent COVID-19 studies, such as serosurveillance and the evaluation of vaccine candidates. In a broader sense, BLI-ISA can be developed as a novel diagnostic platform to evaluate antibodies and other biomolecules in clinical specimens.John V. DzimianskiNicholas Lorig-RoachSara M. O’RourkeDavid L. AlexanderJacqueline M. KimmeyRebecca M. DuBoisNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q John V. Dzimianski Nicholas Lorig-Roach Sara M. O’Rourke David L. Alexander Jacqueline M. Kimmey Rebecca M. DuBois Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
description	Abstract Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide semi-quantitative results. Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies. Our biolayer interferometry immunosorbent assay (BLI-ISA) utilizes single-use biosensors in an automated “dip-and-read” format, providing real-time optical measurements of antigen loading, plasma antibody binding, and antibody isotype detection. Complete semi-quantitative results are obtained in less than 20 min. BLI-ISA meets or exceeds the performance of high complexity methods such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay. Importantly, our method can be immediately implemented on existing BLI platforms for urgent COVID-19 studies, such as serosurveillance and the evaluation of vaccine candidates. In a broader sense, BLI-ISA can be developed as a novel diagnostic platform to evaluate antibodies and other biomolecules in clinical specimens.
format	article
author	John V. Dzimianski Nicholas Lorig-Roach Sara M. O’Rourke David L. Alexander Jacqueline M. Kimmey Rebecca M. DuBois
author_facet	John V. Dzimianski Nicholas Lorig-Roach Sara M. O’Rourke David L. Alexander Jacqueline M. Kimmey Rebecca M. DuBois
author_sort	John V. Dzimianski
title	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
title_short	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
title_full	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
title_fullStr	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
title_full_unstemmed	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
title_sort	rapid and sensitive detection of sars-cov-2 antibodies by biolayer interferometry
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/732073a67aad4d4b950541e95d82a053
work_keys_str_mv	AT johnvdzimianski rapidandsensitivedetectionofsarscov2antibodiesbybiolayerinterferometry AT nicholaslorigroach rapidandsensitivedetectionofsarscov2antibodiesbybiolayerinterferometry AT saramorourke rapidandsensitivedetectionofsarscov2antibodiesbybiolayerinterferometry AT davidlalexander rapidandsensitivedetectionofsarscov2antibodiesbybiolayerinterferometry AT jacquelinemkimmey rapidandsensitivedetectionofsarscov2antibodiesbybiolayerinterferometry AT rebeccamdubois rapidandsensitivedetectionofsarscov2antibodiesbybiolayerinterferometry
_version_	1718393864917614592

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry

Ejemplares similares